Literature DB >> 22159600

Profilin 1 is a potential biomarker for bladder cancer aggressiveness.

Jerome Zoidakis1, Manousos Makridakis, Panagiotis G Zerefos, Vasiliki Bitsika, Sergio Esteban, Maria Frantzi, Konstantinos Stravodimos, Nikolaos P Anagnou, Maria G Roubelakis, Marta Sanchez-Carbayo, Antonia Vlahou.   

Abstract

Of the most important clinical needs for bladder cancer (BC) management is the identification of biomarkers for disease aggressiveness. Urine is a "gold mine" for biomarker discovery, nevertheless, with multiple proteins being in low amounts, urine proteomics becomes challenging. In the present study we applied a fractionation strategy of urinary proteins based on the use of immobilized metal affinity chromatography for the discovery of biomarkers for aggressive BC. Urine samples from patients with non invasive (two pools) and invasive (two pools) BC were subjected to immobilized metal affinity chromatography fractionation and eluted proteins analyzed by 1D-SDS-PAGE, band excision and liquid chromatography tandem MS. Among the identified proteins, multiple corresponded to proteins with affinity for metals and/or reported to be phosphorylated and included proteins with demonstrated association with BC such as MMP9, fibrinogen forms, and clusterin. In agreement to the immobilized metal affinity chromatography results, aminopeptidase N, profilin 1, and myeloblastin were further found to be differentially expressed in urine from patients with invasive compared with non invasive BC and benign controls, by Western blot or Elisa analysis, nevertheless exhibiting high interindividual variability. By tissue microarray analysis, profilin 1 was found to have a marked decrease of expression in the epithelial cells of the invasive (T2+) versus high risk non invasive (T1G3) tumors with occasional expression in stroma; importantly, this pattern strongly correlated with poor prognosis and increased mortality. The functional relevance of profilin 1 was investigated in the T24 BC cells where blockage of the protein by the use of antibodies resulted in decreased cell motility with concomitant decrease in actin polymerization. Collectively, our study involves the application of a fractionation method of urinary proteins and as one main result of this analysis reveals the association of profilin 1 with BC paving the way for its further investigation in BC stratification.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22159600      PMCID: PMC3322560          DOI: 10.1074/mcp.M111.009449

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  63 in total

1.  Assessment of fibrin-fibrinogen degradation products (Accu-Dx) test in bladder cancer patients.

Authors:  M Topsakal; T Karadeniz; M Anaç; S Dönmezer; A Besisik
Journal:  Eur Urol       Date:  2001-03       Impact factor: 20.096

Review 2.  Molecular markers in bladder cancer: a critical appraisal.

Authors:  Badrinath R Konety
Journal:  Urol Oncol       Date:  2006 Jul-Aug       Impact factor: 3.498

3.  In mouse brain profilin I and profilin II associate with regulators of the endocytic pathway and actin assembly.

Authors:  W Witke; A V Podtelejnikov; A Di Nardo; J D Sutherland; C B Gurniak; C Dotti; M Mann
Journal:  EMBO J       Date:  1998-02-16       Impact factor: 11.598

4.  Serum and tissue profiling in bladder cancer combining protein and tissue arrays.

Authors:  Esteban Orenes-Piñero; Rodrigo Barderas; Daniel Rico; J Ignacio Casal; David Gonzalez-Pisano; Jose Navajo; Ferran Algaba; Josep Maria Piulats; Marta Sanchez-Carbayo
Journal:  J Proteome Res       Date:  2010-01       Impact factor: 4.466

5.  Profilin 1 obtained by proteomic analysis in all-trans retinoic acid-treated hepatocarcinoma cell lines is involved in inhibition of cell proliferation and migration.

Authors:  Nan Wu; Wen Zhang; Yong Yang; Yu-Long Liang; Li-Ying Wang; Jia-Wei Jin; Xiu-Mei Cai; Xi-Liang Zha
Journal:  Proteomics       Date:  2006-11       Impact factor: 3.984

Review 6.  The cancer cell secretome: a good source for discovering biomarkers?

Authors:  Maria P Pavlou; Eleftherios P Diamandis
Journal:  J Proteomics       Date:  2010-04-12       Impact factor: 4.044

7.  Analysis of secreted proteins for the study of bladder cancer cell aggressiveness.

Authors:  Manousos Makridakis; Maria G Roubelakis; Vasiliki Bitsika; Veronica Dimuccio; Martina Samiotaki; Sophia Kossida; George Panayotou; Jonathan Coleman; Giovanni Candiano; Nikolaos P Anagnou; Antonia Vlahou
Journal:  J Proteome Res       Date:  2010-06-04       Impact factor: 4.466

8.  Molecular and immunohistologic analyses cannot reliably solve diagnostic variation of flat intraepithelial lesions of the urinary bladder.

Authors:  Shin-ichi Murata; Masachika Iseki; Mitsuru Kinjo; Osamu Matsuzaki; Akira Moriuchi; Hiroshi Ohtani; Takaki Sakurai; Tatsunari Satake; Toyonori Tsuzuki
Journal:  Am J Clin Pathol       Date:  2010-12       Impact factor: 2.493

9.  Matrix metalloproteinases (MMPs) in bladder cancer: the induction of MMP9 by epidermal growth factor and its detection in urine.

Authors:  J E Nutt; G C Durkan; J K Mellon; J Lunec
Journal:  BJU Int       Date:  2003-01       Impact factor: 5.588

10.  Suppression of tumorigenicity in breast cancer cells by the microfilament protein profilin 1.

Authors:  J Janke; K Schlüter; B Jandrig; M Theile; K Kölble; W Arnold; E Grinstein; A Schwartz; L Estevéz-Schwarz; P M Schlag; B M Jockusch; S Scherneck
Journal:  J Exp Med       Date:  2000-05-15       Impact factor: 14.307

View more
  43 in total

Review 1.  Profilin: many facets of a small protein.

Authors:  Rhonda J Davey; Pierre Dj Moens
Journal:  Biophys Rev       Date:  2020-07-13

Review 2.  Developing proteomic biomarkers for bladder cancer: towards clinical application.

Authors:  Maria Frantzi; Agnieszka Latosinska; Leif Flühe; Marie C Hupe; Elena Critselis; Mario W Kramer; Axel S Merseburger; Harald Mischak; Antonia Vlahou
Journal:  Nat Rev Urol       Date:  2015-05-26       Impact factor: 14.432

Review 3.  Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers.

Authors:  Steven L Wood; Margaret A Knowles; Douglas Thompson; Peter J Selby; Rosamonde E Banks
Journal:  Nat Rev Urol       Date:  2013-02-26       Impact factor: 14.432

4.  Subcellular localization and Ser-137 phosphorylation regulate tumor-suppressive activity of profilin-1.

Authors:  Marc I Diamond; Shirong Cai; Aaron Boudreau; Clifton J Carey; Nicholas Lyle; Rohit V Pappu; S Joshua Swamidass; Mina Bissell; Helen Piwnica-Worms; Jieya Shao
Journal:  J Biol Chem       Date:  2015-02-13       Impact factor: 5.157

5.  Silencing profilin-1 inhibits gastric cancer progression via integrin β1/focal adhesion kinase pathway modulation.

Authors:  Ya-Jun Cheng; Zhen-Xin Zhu; Jian-Sheng Zhou; Zun-Qi Hu; Jian-Peng Zhang; Qing-Ping Cai; Liang-Hua Wang
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

6.  Profilin 1 is essential for retention and metabolism of mouse hematopoietic stem cells in bone marrow.

Authors:  Junke Zheng; Zhigang Lu; Fatih Kocabas; Ralph T Böttcher; Mercedes Costell; Xunlei Kang; Xiaoye Liu; Ralph J Deberardinis; Qianming Wang; Guo-Qiang Chen; Hesham Sadek; Cheng Cheng Zhang
Journal:  Blood       Date:  2014-01-02       Impact factor: 22.113

Review 7.  Profilin1 biology and its mutation, actin(g) in disease.

Authors:  Duah Alkam; Ezra Z Feldman; Awantika Singh; Mahmoud Kiaei
Journal:  Cell Mol Life Sci       Date:  2016-09-26       Impact factor: 9.261

Review 8.  Molecular insights on context-specific role of profilin-1 in cell migration.

Authors:  Zhijie Ding; Yong Ho Bae; Partha Roy
Journal:  Cell Adh Migr       Date:  2012-09-01       Impact factor: 3.405

Review 9.  High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment.

Authors:  Oscar Rodriguez Faba; Joan Palou; Alberto Breda; H Villavicencio
Journal:  World J Urol       Date:  2012-10-16       Impact factor: 4.226

10.  Profilin-1 downregulation has contrasting effects on early vs late steps of breast cancer metastasis.

Authors:  Z Ding; M Joy; R Bhargava; M Gunsaulus; N Lakshman; M Miron-Mendoza; M Petroll; J Condeelis; A Wells; P Roy
Journal:  Oncogene       Date:  2013-05-20       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.